Brain atrophy: motor cortex

Quibim

Quibim’s Motor cortex atrophy automatically quantifies the volumes of the right and left precentral gyrus and compares the results with a set of healthy patients. The suite can be used to aid early diagnosis and monitoring of patients with a Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative pathology, which causes movement disorders.

Product specifications

Information source: Vendor
Last updated: Feb. 11, 2022

General
Product name	Brain atrophy: motor cortex
Company	Quibim
Subspeciality	Neuro
Modality	MR
Disease targeted	Amyotrophic lateral sclerosis (ALS)
Key-features	Absolute volume, Relative volume, Brain parenchyma fraction
Suggested use	Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population	Patients associated with Temporal lobe epilepsy (TLE)
Input	MRI T1 GRE 3D T1 Fast Gradient Echo
Input format
Output	One-page structured report: One-page structured report: 3D precentral gyrus render, precentral gyrus segmentation, table with volume statistics, brain parenchyma fraction (BPF), normative graphs of volume and BPF
Output format	DICOM Secondary Capture / PDF
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis	Automatically, right after the image acquisition
Processing time	> 10 minutes
Certification
CE	Certified, Class IIa , MDD
FDA	No or not yet
Market presence
On market since	01-2019
Distribution channels	Alma HEALTH PLATFORM
Countries present (clinical, non-research use)	6
Paying clinical customers (institutes)	5+
Research/test users (institutes)
Pricing
Pricing model	License
Based on	Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers